J&J Unit Slammed With $70M Verdict In Philly Risperdal Trial

By Matt Fair (July 1, 2016, 1:20 PM EDT) -- A Johnson & Johnson unit was slapped with a $70 million verdict on Friday as a Philadelphia jury found that the antipsychotic drug Risperdal had caused an adolescent boy to grow female breasts.

Janssen Pharmaceuticals has lost its latest case over the antipsychotic drug Risperdal in the Philadelphia County Court of Common Pleas, this time to the tune of $70 million, the largest verdict yet. (Credit: AP) The verdict easily eclipses three other victories, totaling $4.75 million, that plaintiffs have notched so far in the first handful of Risperdal-related cases that Janssen Pharmaceuticals Inc. has defended in the Philadelphia County Court...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!